Enanta Pharmaceuticals, Inc. (FRA:9EP)

Market Cap	351.40M +118.3%
Revenue (ttm)	57.12M +0.7%
Net Income	-55.35M
EPS	-2.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	11.80
Previous Close	12.10
Day's Range	11.80 - 12.20
52-Week Range	5.90 - 14.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 120
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9EP

Financial Performance

In fiscal year 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error